Furthermore, the mRNA expression of BDNF and tropomyosin receptor kinase B (TrkB) was found to be reduced in the prefrontal cortex and hippocampus of patients with schizophrenia, indicating that BDNF should be studied as a potential target for antipsychotic medications (17, 18). Here, BDNF is linked to schizophrenia.